NGVT Ingevity Corp

Assenagon Asset Management S.A. significantly reduced its stake in Ingevity Corporation ($NGVT) by selling 42,480 shares, decreasing its holdings by 91.9%. Despite this, other institutions like UBS, Simcoe Capital Management, and American Century Companies Inc. increased their positions in Ingevity. The company currently holds a "Hold" rating from analysts with an average target price of $65.00, reporting a negative P/E ratio and recent EPS of $0.78.

Rice Hall James & Associates LLC reduced its stake in Ingevity Corporation (NYSE:NGVT) by 8.6% in the third quarter, selling 31,595 shares but still holding 334,042 shares valued at approximately $18.44 million. Institutional investors collectively own 91.59% of Ingevity, with various firms adjusting their positions. Analyst ratings for Ingevity are mixed, with a consensus "Hold" rating and a price target of $65.00, though individual targets vary.

Ingevity recently announced a CFO succession plan and the completion of a share repurchase program, buying back 8.37% of its stock for US$201.62 million since August 2022. While these changes and capital return signal a refreshed management focus, the company still faces challenges from pressured Advanced Polymer Technologies (APT) margins and tariff uncertainties. Ingevity's narrative projects significant revenue and earnings growth by 2028, with a fair value estimate of US$68.25.

Squarepoint Ops LLC has acquired 29,690 shares of Ingevity Corporation (NYSE:NGVT) in the second quarter, valued at approximately $1.28 million, establishing a new position in the specialty chemicals company. Institutional ownership of Ingevity is currently very high at 91.59%, with other funds like Vision One Management Partners LP, Range Financial Group LLC, and Teacher Retirement System of Texas also modifying their holdings. Analysts currently have a "Hold" rating on Ingevity with an average target price of $65.00.

Wells Fargo has increased its price target for Ingevity (NGVT) to $60.00 from $55.00, while maintaining an "Equal-Weight" rating. This adjustment reflects continued confidence in the company, though GuruFocus estimates suggest a potential downside from the current price. Ingevity is a chemical manufacturer with diverse segments like Performance Chemicals and Advanced Polymer Technologies.

Wells Fargo & Company has raised its price target for Ingevity (NYSE:NGVT) stock from $55 to $60, while maintaining an "equal weight" rating. Despite this increase, the implied upside is minimal at 0.91%. Other analysts have also issued ratings, with a consensus "Hold" and price target of $65, though opinions are varied from Buy to Sell.